

**For immediate release**

**Oncimmune Holdings plc**  
("Oncimmune" or the "Company")

**Director/PDMR Shareholding**

Oncimmune Holdings plc (AIM: ONC.L), a leading autoantibody profiling company providing research services to the pharmaceutical and biotechnology industries to enable the delivery of precision medicine, announces the acquisition of Subscription Shares by certain board members, and waiver and issue of share options to certain Persons Discharging Managerial Responsibilities pursuant to the Fundraising, as detailed in the Company's announcement dated 18 October 2024 (the "**Fundraising Announcement**"). A summary of the subscribing Directors' shareholdings are as follows:

Subscription for ordinary shares

PDMR	Previous holding of Ordinary Shares	Number of Subscription Shares purchased	Resultant shareholding	Resulting % of Enlarged Share Capital
Alistair Macdonald	55,555	100,000	155,555	0.14
Martin Gouldstone	36,023	66,667	102,690	0.09
John Goold	1,150,000	333,333	1,483,333	1.33

Waiver of options

PDMR	Number of options waived	Date of grant of options waived	Exercise price of options waived	Resulting number of options held
Martin Gouldstone	589,971	7 November 2023	£0.1695	0
Martin Hudson	105,263	8 December 2023	£0.266	0

Grant of options

PDMR	Number of options granted	Exercise price	% of Enlarged Share Capital
Martin Gouldstone	5,588,661	£0.15	5%
Martin Hudson	3,353,197	£0.15	3%

The new options are subject to performance conditions relating to the Company's EBITDA and share price performance, further detail of which is set out in the Fundraising Announcement.

Unless otherwise defined, all capitalised terms used but not defined in this announcement shall have the meaning given to them in the announcement of the Fundraising made by the Company on 18 October 2024.

**For further information:**

**Oncimmune Holdings plc**  
[contact@oncimmune.com](mailto:contact@oncimmune.com)

**Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)**  
Geoff Nash, Callum Davidson, Trisyia Jamaludin (Corporate Finance)  
Nigel Birks (Life Science Specialist Sales)  
Ondraya Swanson (ECM)  
+44 (0) 20 7220 0500

**Zeus (Joint Broker)**  
Dominic King, Dan Bate  
+44 (0)20 3829 5000

The notifications set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

1.	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name:	Alistair Macdonald

1.	<b>Reason for the notification</b>					
a)	Position/status:	Chairman				
b)	Initial notification/Amendment:	Initial notification				
2.	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>					
a)	Name:	Oncimmune Holdings plc				
b)	LEI:	213800HCYIWT6YPI1I02				
3.	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>					
a)	Description of the financial instrument, type of instrument:  Identification code:	Ordinary shares of 1 pence each ("Ordinary Shares")  GB00BYQ94H38				
b)	Nature of the transaction:	Purchase of new ordinary shares				
c)	Price(s) and volume(s):	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>15.0 pence</td> <td>100,000</td> </tr> </tbody> </table>	Price(s)	Volume(s)	15.0 pence	100,000
Price(s)	Volume(s)					
15.0 pence	100,000					
d)	Aggregated information:  · Aggregated volume:  · Aggregated Price:	Single transaction as in 3 c) above				
e)	Date of the transaction:	23 October 2024				
f)	Place of the transaction:	AIM, London Stock Exchange (XLON)				

1.	<b>Details of the person discharging managerial responsibilities/person closely associated</b>			
a)	Name:	Martin Gouldstone		
1.	<b>Reason for the notification</b>			
a)	Position/status:	Chief Executive Officer		
b)	Initial notification/Amendment:	Initial notification		
2.	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>			
a)	Name:	Oncimmune Holdings plc		
b)	LEI:	213800HCYIWT6YPI1I02		
3.	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>			
a)	Description of the financial instrument, type of instrument:  Identification code:	Ordinary shares of 1 pence each ("Ordinary Shares")  GB00BYQ94H38		
b)	Nature of the transaction:	Purchase of new ordinary shares		
c)	Price(s) and volume(s):	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> </tbody> </table>	Price(s)	Volume(s)
Price(s)	Volume(s)			

		<table><tr><td>15.0 pence</td><td>66,667</td></tr></table>	15.0 pence	66,667
15.0 pence	66,667			
d)	Aggregated information:  · Aggregated volume:  · Aggregated Price:	Single transaction as in 3 c) above		
e)	Date of the transaction:	23 October 2024		
f)	Place of the transaction:	AIM, London Stock Exchange (XLON)		

1.	Details of the person discharging managerial responsibilities/person closely associated						
a)	Name:	John Goold					
1.	Reason for the notification						
a)	Position/status:	Non-Executive Director					
b)	Initial notification/Amendment:	Initial notification					
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a)	Name:	Oncimmune Holdings plc					
b)	LEI:	213800HCYIWT6YPI1I02					
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a)	Description of the financial instrument, type of instrument:  Identification code:	Ordinary shares of 1 pence each ("Ordinary Shares")  GB00BYQ94H38					
b)	Nature of the transaction:	Purchase of new ordinary shares					
c)	Price(s) and volume(s):	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>15.0 pence</td><td>333,333</td></tr></table>		Price(s)	Volume(s)	15.0 pence	333,333
Price(s)	Volume(s)						
15.0 pence	333,333						
d)	Aggregated information:  · Aggregated volume:  · Aggregated Price:	Single transaction as in 3 c) above					
e)	Date of the transaction:	23 October 2024					
f)	Place of the transaction:	AIM, London Stock Exchange (XLON)					

1.	<b>Details of the person discharging managerial responsibilities/person closely associated</b>	
a)	Name:	Martin Gouldstone
1.	<b>Reason for the notification</b>	
a)	Position/status:	Chief Executive Officer
b)	Initial notification/Amendment:	Initial notification

2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name:	Oncimmune Holdings plc				
b)	LEI:	213800HCYIWT6YPI1I02				
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a)	Description of the financial instrument, type of instrument:  Identification code:	Ordinary shares of 1 pence each ("Ordinary Shares")  GB00BYQ94H38				
b)	Nature of the transaction:	Waiver of options				
c)	Price(s) and volume(s):	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>16.95 pence</td><td>589,971</td></tr></table>	Price(s)	Volume(s)	16.95 pence	589,971
Price(s)	Volume(s)					
16.95 pence	589,971					
d)	Aggregated information:  · Aggregated volume:  · Aggregated Price:	Single transaction as in 3 c) above				
e)	Date of the transaction:	8 November 2024				
f)	Place of the transaction:	Outside a trading venue				

1.	Details of the person discharging managerial responsibilities/person closely associated						
a)	Name:	Martin Hudson					
1.	Reason for the notification						
a)	Position/status:	Finance Director					
b)	Initial notification/Amendment:	Initial notification					
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a)	Name:	Oncimmune Holdings plc					
b)	LEI:	213800HCYIWT6YPI1I02					
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a)	Description of the financial instrument, type of instrument:  Identification code:	Ordinary shares of 1 pence each ("Ordinary Shares")  GB00BYQ94H38					
b)	Nature of the transaction:	Waiver of options					
c)	Price(s) and volume(s):	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>26.6 pence</td><td>105,263</td></tr></table>		Price(s)	Volume(s)	26.6 pence	105,263
Price(s)	Volume(s)						
26.6 pence	105,263						

d)	Aggregated information: · Aggregated volume: · Aggregated Price:	Single transaction as in 3 c) above
e)	Date of the transaction:	8 November 2024
f)	Place of the transaction:	Outside a trading venue

1.	<b>Details of the person discharging managerial responsibilities/person closely associated</b>					
a)	Name:	Martin Gouldstone				
1.	<b>Reason for the notification</b>					
a)	Position/status:	Chief Executive Officer				
b)	Initial notification/Amendment:	Initial notification				
2.	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>					
a)	Name:	Oncimmune Holdings plc				
b)	LEI:	213800HCYIWT6YPI1I02				
3.	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>					
a)	Description of the financial instrument, type of instrument:  Identification code:	Ordinary shares of 1 pence each ("Ordinary Shares")  GB00BYQ94H38				
b)	Nature of the transaction:	Grant of options				
c)	Price(s) and volume(s):	<table border="1"> <thead> <tr> <th>Price(s)</th><th>Volume(s)</th></tr> </thead> <tbody> <tr> <td>15 pence</td><td>5,588,661</td></tr> </tbody> </table>	Price(s)	Volume(s)	15 pence	5,588,661
Price(s)	Volume(s)					
15 pence	5,588,661					
d)	Aggregated information: · Aggregated volume: · Aggregated Price:	Single transaction as in 3 c) above				
e)	Date of the transaction:	8 November 2024				
f)	Place of the transaction:	Outside a trading venue				

1.	<b>Details of the person discharging managerial responsibilities/person closely associated</b>	
a)	Name:	Martin Hudson
1.	<b>Reason for the notification</b>	
a)	Position/status:	Finance Director
b)	Initial notification/Amendment:	Initial notification

2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a)	Name:	Oncimmune Holdings plc					
b)	LEI:	213800HCYIWT6YPI1I02					
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a)	Description of the financial instrument, type of instrument:  Identification code:	Ordinary shares of 1 pence each ("Ordinary Shares")  GB00BYQ94H38					
b)	Nature of the transaction:	Grant of options					
c)	Price(s) and volume(s):	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>15 pence</td><td>3,353,197</td></tr></table>		Price(s)	Volume(s)	15 pence	3,353,197
Price(s)	Volume(s)						
15 pence	3,353,197						
d)	Aggregated information:  · Aggregated volume:  · Aggregated Price:	Single transaction as in 3 c) above					
e)	Date of the transaction:	8 November 2024					
f)	Place of the transaction:	Outside a trading venue					

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHFLLFFZLFFBE